-- Linamar (LNR.TO) 股价昨日下跌超过 12%,该公司周三收盘后表示,鉴于近期 232 条款关税的修订,公司维持其 2026 财年全年业绩预期不变。 该公司表示,修订后的 232 条款关税预计不会对其移动出行业务造成影响,因为这些产品要么免征关税,要么关税相关成本由客户承担。 该公司指出,相比之下,工业业务中的部分产品受到的影响“更为显著”,并表示正在“积极评估这种影响的范围”。 一份声明指出,Linamar团队正在对近期232条款关税的变更进行“全面审查”,并采取各种应对策略,包括调整采购、定价和其他手段。声明称:“尽管评估仍在进行中,但Linamar在关税环境管理方面拥有成熟的流程和经验,能够有效应对。我们将在2026年5月6日发布的2026年第一季度业绩报告中提供更清晰的信息。” 声明还补充道:在对232条款关税修正案进行初步评估后,公司维持其2026年销售增长、调整后每股收益增长和自由现金流的预期。 Linamar执行主席琳达·哈森弗拉茨表示:“在当今瞬息万变的地缘政治环境下,我们比以往任何时候都更需要专注于长期基本面和原则。这对于企业和政府都至关重要。美国是我们最大的贸易伙伴;我们彼此紧密相连,对彼此都至关重要。”让我们先就232号关税和美墨加协定的延续达成协议,剩下的事情商业上自然会解决。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.